Cybin
Toronto
ON
Canada
149 articles about Cybin
-
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
4/18/2024
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry.
-
Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
4/17/2024
Numinus Wellness Inc. is proud to announce that its research site, Cedar Clinical Research has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").
-
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
4/16/2024
Cybin Inc. today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder (“MDD”).
-
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4/10/2024
Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, taking place April 16-17, 2024 in Toronto, Ontario.
-
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
3/18/2024
Cybin Inc today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX.
-
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
3/15/2024
Cybin Inc. today announced the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary DMT molecule in development for the treatment of GAD.
-
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
3/14/2024
Cybin Inc. today announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder (“MDD”).
-
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
2/27/2024
Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference.
-
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
2/14/2024
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended December 31, 2023, and recent business highlights.
-
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
2/7/2024
Cybin Inc. today announced that the Japan Patent (“JP”) Office has granted JP patents 2023-500532 and 2023-533436.
-
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
1/23/2024
Cybin Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug (“IND”) application for CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of Generalized Anxiety Disorder (“GAD”).
-
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
1/8/2024
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”) today announced positive safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data from its Phase 1 studies of CYB004 (IV) and SPL028 (IV and IM) in healthy volunteers.
-
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
1/4/2024
Cybin Inc. today outlined its recent positive Phase 2 CYB003 topline results in MDD and near-term milestones across its clinical-stage deuterated psilocybin and dDMT programs in development for the treatment of multiple mental health conditions.
-
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
12/6/2023
Cybin Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,834,410 in support of its CYB003 program.
-
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
12/5/2023
Cybin Inc. today announced the presentation of four posters at the America College of Neuropsychopharmacology (“ACNP”) annual meeting taking place December 3-6, 2023, in Tampa, Florida.
-
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
11/30/2023
Cybin Inc. today announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“MDD”).
-
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
11/20/2023
Cybin Inc. today announced that it will discuss its topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder, as part of an R&D investor briefing.
-
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
11/15/2023
Cybin Inc. today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience (“SFN”) taking place November 11-15, 2022, in Washington, D.C.
-
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
11/15/2023
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.
-
Cybin Announces up to US$64 Million Offering of Units
11/10/2023
Cybin Inc. is pleased to announce a firm commitment underwritten offering (the “ Offering ”) of 66,666,667 units of the Company (the “ Units ”) to one of the Company’s largest existing institutional shareholders and new institutional investors at a price of US$0.45 per Unit for gross proceeds of approximately US$30 million.